• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用一个实际案例——溶酶体α-半乳糖苷酶的致病性突变——来挑战遗传变异注释的流行工具。

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.

机构信息

Dipartimento di Biologia, Complesso di Monte Sant'Angelo, Università Federico II, VIA Cinthia, 80126, Napoli, Italy.

Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.

出版信息

BMC Bioinformatics. 2018 Nov 30;19(Suppl 15):433. doi: 10.1186/s12859-018-2416-7.

DOI:10.1186/s12859-018-2416-7
PMID:30497360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6266955/
Abstract

BACKGROUND

Severity gradation of missense mutations is a big challenge for exome annotation. Predictors of deleteriousness that are most frequently used to filter variants found by next generation sequencing, produce qualitative predictions, but also numerical scores. It has never been tested if these scores correlate with disease severity.

RESULTS

wANNOVAR, a popular tool that can generate several different types of deleteriousness-prediction scores, was tested on Fabry disease. This pathology, which is caused by a deficit of lysosomal alpha-galactosidase, has a very large genotypic and phenotypic spectrum and offers the possibility of associating a quantitative measure of the damage caused by mutations to the functioning of the enzyme in the cells. Some predictors, and in particular VEST3 and PolyPhen2 provide scores that correlate with the severity of lysosomal alpha-galactosidase mutations in a statistically significant way.

CONCLUSIONS

Sorting disease mutations by severity is possible and offers advantages over binary classification. Dataset for testing and training in silico predictors can be obtained by transient transfection and evaluation of residual activity of mutants in cell extracts. This approach consents to quantitative data for severe, mild and non pathological variants.

摘要

背景

错义突变严重程度分级是外显子组注释的一大挑战。最常用于筛选下一代测序发现的变体的有害性预测因子是产生定性预测的,但也有数值评分。这些评分是否与疾病严重程度相关从未得到过验证。

结果

wANNOVAR 是一种常用的工具,可以生成几种不同类型的有害性预测评分,在法布里病中进行了测试。这种由溶酶体α-半乳糖苷酶缺乏引起的疾病具有非常大的基因型和表型谱,并提供了将突变引起的酶功能损伤的定量测量与细胞中突变的严重程度相关联的可能性。一些预测因子,特别是 VEST3 和 PolyPhen2,提供的评分与溶酶体α-半乳糖苷酶突变的严重程度呈统计学显著相关。

结论

通过严重程度对疾病突变进行分类是可行的,并且优于二进制分类。用于测试和训练计算预测因子的数据集可以通过瞬时转染和细胞提取物中突变体残余活性的评估获得。这种方法允许对严重、轻度和非病理性变体进行定量数据处理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/4452a769a0f7/12859_2018_2416_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/459776e66ed5/12859_2018_2416_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/f6efe372e499/12859_2018_2416_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/4452a769a0f7/12859_2018_2416_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/459776e66ed5/12859_2018_2416_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/f6efe372e499/12859_2018_2416_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d44/6266955/4452a769a0f7/12859_2018_2416_Fig3_HTML.jpg

相似文献

1
Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.用一个实际案例——溶酶体α-半乳糖苷酶的致病性突变——来挑战遗传变异注释的流行工具。
BMC Bioinformatics. 2018 Nov 30;19(Suppl 15):433. doi: 10.1186/s12859-018-2416-7.
2
Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations.法布里病中的分子损伤:α-半乳糖苷酶A病理突变的特征与预测
Proteins. 2015 Jan;83(1):91-104. doi: 10.1002/prot.24708. Epub 2014 Nov 18.
3
Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.法布里病:α-半乳糖苷酶A双重突变及D313Y血浆酶假性缺陷等位基因的特征
Hum Mutat. 2003 Dec;22(6):486-92. doi: 10.1002/humu.10275.
4
[alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].法布里病(α-半乳糖苷酶缺乏症)中的α-半乳糖苷酶基因突变及其表达产物
Rinsho Byori. 1997 Feb;45(2):127-35.
5
Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.在具有残余酶活性的法布里病患者中鉴定出的突变α-半乳糖苷酶A酶:生化特性及1-脱氧半乳糖野尻霉素对正常细胞内加工的恢复作用
Biochem J. 2007 Sep 1;406(2):285-95. doi: 10.1042/BJ20070479.
6
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.法布里病的药理学伴侣治疗:从计算机预测到体外试验。
Orphanet J Rare Dis. 2011 Oct 17;6:66. doi: 10.1186/1750-1172-6-66.
7
Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.α-半乳糖苷酶A基因中的20种新突变导致法布里病。
Mol Med. 1999 Dec;5(12):806-11.
8
Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).安德森-法布里病和庞贝病变异溶酶体酸性糖苷酶的功能分析在人胚肾上皮细胞系(HEK 293 T)中。
J Inherit Metab Dis. 2012 Mar;35(2):325-34. doi: 10.1007/s10545-011-9395-4. Epub 2011 Oct 5.
9
[Fabry disease (alpha-galactosidase deficiency)].[法布里病(α-半乳糖苷酶缺乏症)]
Nihon Rinsho. 1995 Dec;53(12):2952-9.
10
Comparative in vitro expression study of four Fabry disease causing mutations at glutamine 279 of the alpha-galactosidase A protein.α-半乳糖苷酶A蛋白第279位谷氨酰胺处四个导致法布里病的突变的体外比较表达研究。
Hum Hered. 2004;57(3):138-41. doi: 10.1159/000079244.

引用本文的文献

1
A Maternal Loss-of-Function Variant in KHDC3L Gene Causes a Range of Adverse Pregnancy Outcomes: A Case Report.KHDC3L基因的母源功能丧失变异导致一系列不良妊娠结局:一例病例报告。
Mol Genet Genomic Med. 2025 Jan;13(1):e70051. doi: 10.1002/mgg3.70051.
2
Enhancing Missense Variant Pathogenicity Prediction with MissenseNet: Integrating Structural Insights and ShuffleNet-Based Deep Learning Techniques.利用 MissenseNet 增强错义变异致病性预测:整合结构见解和基于 ShuffleNet 的深度学习技术。
Biomolecules. 2024 Sep 2;14(9):1105. doi: 10.3390/biom14091105.
3
Congenital disorders of glycosylation: narration of a story through its patents.

本文引用的文献

1
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease.体外酶活性测定以检测法布里病和庞贝病中药物伴侣分子的反应性
J Vis Exp. 2017 Dec 20(130):56550. doi: 10.3791/56550.
2
Ten quick tips for machine learning in computational biology.计算生物学中机器学习的十条快速提示。
BioData Min. 2017 Dec 8;10:35. doi: 10.1186/s13040-017-0155-3. eCollection 2017.
3
Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines.评估 ACMG/AMP 临床变异解读指南中使用的计算机算法。
先天性糖基化障碍:从专利角度讲述一个故事。
Orphanet J Rare Dis. 2023 Aug 29;18(1):247. doi: 10.1186/s13023-023-02852-w.
4
Novel genetic variants of KHDC3L and other members of the subcortical maternal complex associated with Beckwith-Wiedemann syndrome or Pseudohypoparathyroidism 1B and multi-locus imprinting disturbances.与贝克威斯-威德曼综合征或假性甲状旁腺功能减退症 1B 以及多基因印记紊乱相关的 KHDC3L 及皮质下母系复合体其他成员的新型遗传变异。
Clin Epigenetics. 2022 May 28;14(1):71. doi: 10.1186/s13148-022-01292-w.
5
Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease.挑战传统的遗传变异解读方法:法布瑞氏病的启示。
Clin Genet. 2022 Apr;101(4):390-402. doi: 10.1111/cge.14102. Epub 2021 Dec 28.
6
Protective Role of a Variant on Severe COVID-19 Outcome in Young Males and Elderly Women.一种变体对年轻男性和老年女性严重新冠病毒疾病结局的保护作用
Genes (Basel). 2021 Apr 19;12(4):596. doi: 10.3390/genes12040596.
7
Loss-of-function maternal-effect mutations of PADI6 are associated with familial and sporadic Beckwith-Wiedemann syndrome with multi-locus imprinting disturbance.PADI6 的功能丧失型母源性效应突变与多基因印记紊乱相关的家族性和散发性 Beckwith-Wiedemann 综合征有关。
Clin Epigenetics. 2020 Sep 14;12(1):139. doi: 10.1186/s13148-020-00925-2.
8
Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants.评估 NGS 时代的溶酶体疾病:新型罕见变异的鉴定。
Int J Mol Sci. 2020 Sep 1;21(17):6355. doi: 10.3390/ijms21176355.
9
GLA missense and promoter variants co-segregating in a Chinese family with Fabry disease.在中国一个法布里病家族中共同分离的GLA错义突变和启动子变异体。
Ann Transl Med. 2020 Jul;8(14):865. doi: 10.21037/atm-19-4510.
Genome Biol. 2017 Nov 28;18(1):225. doi: 10.1186/s13059-017-1353-5.
4
Ensembl 2018.Ensembl 2018.
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761. doi: 10.1093/nar/gkx1098.
5
SDM: a server for predicting effects of mutations on protein stability.SDM:一种用于预测突变对蛋白质稳定性影响的服务器。
Nucleic Acids Res. 2017 Jul 3;45(W1):W229-W235. doi: 10.1093/nar/gkx439.
6
The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.法布里病的广泛表型谱需要分级诊断和个性化治疗:一项荟萃分析有助于区分错义突变。
Int J Mol Sci. 2016 Dec 1;17(12):2010. doi: 10.3390/ijms17122010.
7
Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.在人溶酶体α-半乳糖苷酶上鉴定出变构结合位点,为法布里病的新型药理伴侣分子开辟了道路。
PLoS One. 2016 Oct 27;11(10):e0165463. doi: 10.1371/journal.pone.0165463. eCollection 2016.
8
M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity.M-CAP 以高灵敏度消除临床外显子组中大多数意义不明的变异。
Nat Genet. 2016 Dec;48(12):1581-1586. doi: 10.1038/ng.3703. Epub 2016 Oct 24.
9
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.用于识别拟接受米加司他治疗的法布里病患者的药物遗传学验证。
Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22.
10
Analysis of protein-coding genetic variation in 60,706 humans.对60706名人类的蛋白质编码基因变异进行分析。
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.